Prasugrel

Generic Name: Prasugrel

Brand Names: Effient, Efient, Prasugrel Viatris (previously Prasugrel Mylan)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₀FNO_₃S

CAS Number: 150322-43-3

Unique Ingredient Identifier: 34K66TBT99

Background: Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.

Indication: 用于心力衰竭、卒中、不稳定心绞痛等心脑血管疾病以及有急性冠状动脉综合征需要进行经皮冠脉介入术的患者。

Associated Conditions: Cardiovascular Events

Clinical Trials

Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting

Phase 4

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Ticagrelor
Drug: Prasugrel

First Posted Date: 2015-07-01

Last Posted Date: 2019-04-25

Lead Sponsor: Korea University Anam Hospital

Target Recruit Count: 60

Registration Number: NCT02487732

Locations: 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of

Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by Ticagrelor

Phase 4

Conditions: Myocardial Infarction

Interventions: Drug: Prasugrel
Drug: Ticagrelor

First Posted Date: 2015-04-21

Last Posted Date: 2018-05-03

Lead Sponsor: Amsterdam UMC, location VUmc

Target Recruit Count: 110

Registration Number: NCT02422888

Locations: 🇳🇱
VU University Medical Center, Amsterdam, Noord-Holland, Netherlands

P3AMI Antiplatelet Trial

Phase 4

Completed

Conditions: Heart Attack

Interventions: Drug: Prasugrel
Drug: Clopidogrel
Drug: ticagrelor

First Posted Date: 2015-03-03

Last Posted Date: 2020-02-10

Lead Sponsor: The Royal Wolverhampton Hospitals NHS Trust

Target Recruit Count: 87

Registration Number: NCT02376283

Locations: 🇬🇧
The Royal Wolverhampton NHS Trust, Wolverhampton, West Midlands, United Kingdom

High "on Treatment" Platelet Reactivity in the Intensive Care Unit

Phase 2

Conditions: Critical Illness

Interventions: Drug: prasugrel
Drug: acetylsalicylic acid
Drug: ticagrelor
Drug: clopidogrel

First Posted Date: 2014-11-07

Last Posted Date: 2019-08-20

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 200

Registration Number: NCT02285751

Locations: 🇦🇹
General Hospital, Vienna, Austria

Ticagrelor and Endothelial Function

Phase 4

Conditions: Antiplatelet Agents; Endothelial Function; Pleotropic Effects

Interventions: Drug: prasugrel
Drug: ticagrelor

First Posted Date: 2014-10-10

Last Posted Date: 2014-10-10

Lead Sponsor: Hotel Dieu de France Hospital

Target Recruit Count: 20

Registration Number: NCT02261922

Locations: 🇱🇧
Hotel Dieu de France Hospital, Achrafieh, Beirut, Lebanon

Study of Platelet Function After Administration of Aspirin Versus Lysine Acetylsalicylate

Phase 1

Completed

Conditions: Adverse Effect of Antithrombotic Drugs

Interventions: Drug: acetylsalicylic acid
Drug: lysine acetylsalicylate
Drug: prasugrel

First Posted Date: 2014-09-17

Last Posted Date: 2014-09-17

Lead Sponsor: David Vivas

Target Recruit Count: 30

Registration Number: NCT02243137

Locations: 🇪🇸
Hospital Clínico San Carlos, Madrid, Spain

Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis

Phase 4

Completed

Conditions: Acute Coronary Syndrome
Platelet Function

Interventions: Drug: Prasugrel
Drug: Ticagrelor

First Posted Date: 2014-08-13

Last Posted Date: 2017-05-23

Lead Sponsor: Federal University of São Paulo

Target Recruit Count: 50

Registration Number: NCT02215993

Locations: 🇧🇷
Federal University of São Paulo, São Paulo, Brazil

Pharmacological Effects of Crushing Prasugrel in STEMI Patients

Phase 4

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: prasugrel

First Posted Date: 2014-08-08

Last Posted Date: 2016-12-28

Lead Sponsor: University of Florida

Target Recruit Count: 52

Registration Number: NCT02212028

Locations: 🇺🇸
University of Florida, Jacksonville, Florida, United States

Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial)

Phase 4

Conditions: Acute Coronary Syndrome

Interventions: Device: BS-DES (Biostable polymer drug-eluting stent)
Device: BD-DES (Biodegradable polymer drug-eluting stent)
Drug: Prasugrel 5mg